Cost Comparison of Benign Prostatic Hyperplasia Treatment Options
Purpose of Review
To provide an economic context within which to consider treatment options for benign prostatic hyperplasia (BPH). To this end, this review provides a comparison of the costs of combination medical therapy, operative treatment, and office-based therapies for BPH from a payer perspective.
Analysis of Medicare charges from the authors’ institution, as well as local retail costs of medication, demonstrated a wide range in costs of commonly used BPH treatments. In this study, interventions for BPH reached cost equivalence with combination medical therapy within 6 months to 8 years.
A myriad of options for managing men with symptomatic BPH exist. It is prudent not only to consider surgeon preference and patient-specific factors when selecting a treatment but also to understand the economic impact different BPH therapies confer.
KeywordsBenign prostatic hyperplasia Lower urinary tract symptoms Cost analysis Medication therapy management
Compliance with Ethical Standards
Conflict of Interest
Molly E. DeWitt-Foy and Bradley C. Gill each declare no potential conflicts of interest.
James C. Ulchaker reports personal fees from Boston Scientific and Foretc Medical.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 7.Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.CrossRefGoogle Scholar
- 8.Kaplan SA, et al. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):182.Google Scholar
- 9.Foster HE, Barry MJ, Dahm P, Gahndi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatichyperplasia: AUA Guideline. J Urol. 2018;200(3):612–9.Google Scholar
- 10.Varda BK, Wang Y, Chung BI, Lee RS, Kurtz MP, Nelson CP, et al. Has the robot caught up? National trends in utilization, preoperative outcomes, and cost for open, laparoscopic, and robotic pediatric pyeloplasty in the United States from 2003 to 2015. J Pediatr Urol. 2018;14(4):336.e1–8.CrossRefGoogle Scholar
- 11.•• Kaplan AL, et al. Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC). Healthcare. 2015;3(1):43–8. Use of time-driven activity-based costing to compare costs associated with five different surgical options for BPH treatment. CrossRefGoogle Scholar
- 14.•• Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43. Cost-effectiveness analysis of six current BPH treatments from payers’ perspective, using IPSS scores, adverse events, and retreatment rates to estimate ICERs for pairs of treatments. CrossRefGoogle Scholar
- 17.•• Chung ASJ, Wood HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–7. Evaluation of novel minimally invasive surgical options through review of literature, with particular focus on studies published in the preceding five years. Google Scholar
- 19.Roehrborn CG, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T study. Can J Urol Int. 2017;24(3):8802–13.Google Scholar
- 20.Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 months results of the MedLift study. Prostate Cancer Prostatic Dis. 2018. https://doi.org/10.1038/s41391-018-0118-x.
- 21.•• Davis NF, et al. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. World J Urol. 2018;37:873–8. https://doi.org/10.1007/s00345-018-2454-9. Use of a prospective, multicenter registry across Europe to evaluate the relative cost of BPH medical therapy and TURP. CrossRefPubMedGoogle Scholar
- 23.Benejam-Gual JM, et al. Cost effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-photo vaporization 120 W versus transurethral resection of the prostate. Actas Urol Esp. 2014;38(4):238–43.CrossRefGoogle Scholar
- 24.•• Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018;19(9):72. Review of the relative costs of BPH therapy including medical therapy, operating room based surgical therapy and office-based procedures from the payers’ perspective. Google Scholar